Generic-Drug Users Can't Pin Brand-Name Cos., NJ Court Says

Law360, New York (June 28, 2012, 6:01 PM EDT) -- A New Jersey judge dismissed allegations Tuesday from users of generic versions of the heartburn medication Reglan that the drug's brand-name manufacturers, including Wyeth LLC, misrepresented its risks, finding the U.S. Supreme Court's Mensing decision did not address brand-name companies' duty to generics users.

Plaintiffs in eight cases had argued to Judge Carol Higbee that Mensing opened up brand-name drugmakers to failure-to-warn and other claims from generics users. They did not themselves bring failure-to-warn allegations against Reglan manufacturers Wyeth, Schwarz Pharma Inc. and Alaven Pharmaceutical LLC,...
To view the full article, register now.